Higher UPF-consumption was linked to worse knee OA outcomes among women, including higher pain scores, worse physical function, and thinner knee cartilage.

There has been an increase in certain cardiometabolic risk factors and a decrease in others among adults in the United States in recent years.

Compared with those with overweight and normal weight, people with obesity were more likely to report financial hardship and food insecurity.

There is increased risk for atrial fibrillation in patients with implanted devices exposed to hot outdoor temperatures.

Traditional cardiovascular risk assessment tools underperform among individuals with metabolic dysfunction-associated steatotic liver disease.

Early abdominal CT may be warranted among patients with unknown or uncertain biochemical screening results for primary aldosteronism.

MASLD rates have decreased, whereas liver fibrosis and cirrhosis rates have increased among US patients with type 2 diabetes since 2017.

LT4 plus L3 therapy vs LT4 therapy alone was associated with reduced mortality and dementia risks among patients with hypothyroidism.

The global prevalence of OA attributed to high BMI has steadily increased over the past 3 decades, particularly among women and in high-SDI regions.

There is decreased risk for CV events and mortality in patients with cardiac autonomic neuropathy that receive intensive glycemic treatment.

Diabetes remission was more likely and laparoscopic surgery was less likely among women than men with paragangliomas and pheochromocytomas.

SGLT2 inhibitors, compared with GLP-1 RAs, were associated with lower risks for osteoarthritis and joint replacement surgery among patients with T2D.